Richard M Hoffman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4652745/publications.pdf

Version: 2024-02-01

159 papers 8,322 citations

44069 48 h-index 49909 87 g-index

159 all docs

159 docs citations

159 times ranked 7957 citing authors

#	Article	IF	CITATIONS
1	Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. New England Journal of Medicine, 2013, 368, 436-445.	27.0	803
2	Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study. Journal of the National Cancer Institute, 2004, 96, 1358-1367.	6.3	577
3	5-YEAR URINARY AND SEXUAL OUTCOMES AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY. Journal of Urology, 2005, 173, 1701-1705.	0.4	426
4	Racial and Ethnic Differences in Advanced-Stage Prostate Cancer: the Prostate Cancer Outcomes Study. Journal of the National Cancer Institute, 2001, 93, 388-395.	6. 3	362
5	Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes Study. Journal of Clinical Oncology, 2001, 19, 3750-3757.	1.6	244
6	Screening for Prostate Cancer. New England Journal of Medicine, 2011, 365, 2013-2019.	27.0	183
7	Factors Associated With Initial Therapy for Clinically Localized Prostate Cancer: Prostate Cancer Outcomes Study. Journal of the National Cancer Institute, 2001, 93, 1864-1871.	6.3	180
8	Step-down management of gastroesophageal reflux disease. Gastroenterology, 2001, 121, 1095-1100.	1.3	177
9	Quality of Life Following Localized Prostate Cancer Treated Initially with Androgen Deprivation Therapy or No Therapy. Journal of the National Cancer Institute, 2002, 94, 430-437.	6.3	173
10	General Quality of Life 2 Years Following Treatment for Prostate Cancer: What Influences Outcomes? Results From the Prostate Cancer Outcomes Study. Journal of Clinical Oncology, 2003, 21, 1147-1154.	1.6	173
11	Decision-Making Processes for Breast, Colorectal, and Prostate Cancer Screening: The DECISIONS Survey. Medical Decision Making, 2010, 30, 53-64.	2.4	165
12	Surgery for herniated lumbar discs. Journal of General Internal Medicine, 1993, 8, 487-496.	2.6	148
13	Effect of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population–Based Cohort of Men With Prostate Cancer. Annals of Internal Medicine, 2013, 158, 709.	3.9	147
14	Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer, 2003, 97, 1653-1662.	4.1	145
15	Intensified Blood Glucose Monitoring Improves Glycemic Control in Stable, Insulin-Treated Veterans With Type 2 Diabetes: The Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care, 2003, 26, 1759-1763.	8.6	139
16	Health Outcomes After External-Beam Radiation Therapy for Clinically Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. Journal of Clinical Oncology, 2001, 19, 2517-2526.	1.6	131
17	Prostate Cancer Screening Decisions. Archives of Internal Medicine, 2009, 169, 1611-8.	3.8	122
18	5-Year Urinary and Sexual Outcomes After Radical Prostatectomy: Results From the Prostate Cancer Outcomes Study. Journal of Urology, 2008, 179, S40-4.	0.4	117

#	Article	lF	CITATIONS
19	TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING THERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER: PATIENT REPORTED USE AND OUTCOMES FROM THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROSTATE CANCER OUTCOMES STUDY. Journal of Urology, 2005, 174, 646-650.	0.4	107
20	Factors affecting diabetes knowledge in Type 2 diabetic veterans. Diabetologia, 2003, 46, 1170-1178.	6.3	100
21	Evaluating dizziness. American Journal of Medicine, 1999, 107, 468-478.	1.5	93
22	Racial differences in initial treatment for clinically localized prostate cancer. Journal of General Internal Medicine, 2003, 18, 845-853.	2.6	89
23	Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer. Journal of the National Cancer Institute, 2013, 105, 711-718.	6.3	89
24	Lack of Shared Decision Making in Cancer Screening Discussions. American Journal of Preventive Medicine, 2014, 47, 251-259.	3.0	87
25	Patient Adherence to Screening for Lung Cancer in the US. JAMA Network Open, 2020, 3, e2025102.	5.9	86
26	Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population. JAMA Internal Medicine, 2017, 177, 967.	5.1	81
27	Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. Journal of Clinical Oncology, 2017, 35, 2306-2314.	1.6	81
28	Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU International, 2011, 107, 576-584.	2.5	80
29	Laser Prostatectomy Versus Transurethral Resection for Treating Benign Prostatic Obstruction: A Systematic Review. Journal of Urology, 2003, 169, 210-215.	0.4	72
30	Lung Cancer Screening. Medical Clinics of North America, 2017, 101, 769-785.	2.5	72
31	Plummer-Vinson Syndrome. Archives of Internal Medicine, 1995, 155, 2008.	3.8	68
32	How Common Are Various Causes of Dizziness? A Critical Review. Southern Medical Journal, 2000, 93, 160-167.	0.7	68
33	A Probabilistic Model for Predicting Hypoglycemia in Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2004, 164, 1445.	3.8	68
34	Attitudes and Beliefs of Primary Care Providers in New Mexico About Lung Cancer Screening Using Low-Dose Computed Tomography. Preventing Chronic Disease, 2015, 12, E108.	3.4	68
35	Racial/Ethnic Differences in Functional Outcomes in the 5 Years After Diagnosis of Localized Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 4193-4201.	1.6	67
36	Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: A randomized, controlled trialâ ⁺ t. Preventive Medicine, 2010, 50, 297-299.	3.4	66

3

#	Article	IF	CITATIONS
37	PREDICTING EXTRACAPSULAR EXTENSION OF PROSTATE CANCER IN MEN TREATED WITH RADICAL PROSTATECTOMY: RESULTS FROM THE POPULATION BASED PROSTATE CANCER OUTCOMES STUDY. Journal of Urology, 1999, 162, 1341-1345.	0.4	64
38	Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer, 2004, 101, 2011-2019.	4.1	64
39	Lung Cancer Screening with Low-Dose CT: a Meta-Analysis. Journal of General Internal Medicine, 2020, 35, 3015-3025.	2.6	60
40	Expressions of Machismo in Colorectal Cancer Screening Among New Mexico Hispanic Subpopulations. Qualitative Health Research, 2012, 22, 546-559.	2.1	59
41	Variable stiffness colonoscope versus regular adult colonoscope: meta-analysis of randomized controlled trials. Endoscopy, 2009, 41, 17-24.	1.8	58
42	Prostate-specific antigen testing accuracy in community practice. BMC Family Practice, 2002, 3, 19.	2.9	57
43	Influence of Publication of US and European Prostate Cancer Screening Trials on PSA Testing Practices. Journal of the National Cancer Institute, 2011, 103, 520-523.	6.3	57
44	Antioxidants and the Prevention of Coronary Heart Disease. Archives of Internal Medicine, 1995, 155, 241.	3.8	55
45	Microwave thermotherapy for benign prostatic hyperplasia. , 2007, , CD004135.		53
46	Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. Journal of General Internal Medicine, 2000, 15, 739-748.	2.6	50
47	Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasia: a systematic review. BJU International, 2004, 94, 1031-1036.	2.5	50
48	The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. Journal of Urology, 2016, 195, 321-329.	0.4	50
49	Challenges Implementing Lung Cancer Screening in Federally Qualified Health Centers. American Journal of Preventive Medicine, 2018, 54, 568-575.	3.0	49
50	Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU International, 2006, 98, 335-340.	2.5	48
51	Patient Perspectives on Low-Dose Computed Tomography for Lung Cancer Screening, New Mexico, 2014. Preventing Chronic Disease, 2016, 13, E108.	3.4	47
52	Health Outcomes in Older Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. American Journal of Medicine, 2006, 119, 418-425.	1.5	44
53	Comparison of Self-reported Initial Treatment with Medical Records: Results from the Prostate Cancer Outcomes Study. American Journal of Epidemiology, 2001, 154, 582-587.	3.4	43
54	Prescription opioid abuse, chronic pain, and primary care: A Co-Occurring Disorders Clinic in the chronic disease model. Journal of Substance Abuse Treatment, 2012, 43, 446-450.	2.8	43

#	Article	IF	CITATIONS
55	Modifiable Risk Factors for Incident Heart Failure in the Coronary Artery Surgery Study. Archives of Internal Medicine, 1994, 154, 417.	3.8	40
56	Hypoglycemia in type 2 diabetes: a critical review. Biomedicine and Pharmacotherapy, 2004, 58, 551-559.	5.6	40
57	Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy. Journal of General Internal Medicine, 2007, 22, 1305-1310.	2.6	40
58	Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer, 2005, 5, 27.	2.6	39
59	Diagnostic Accuracy and Clinical Utility of Thermography for Lumbar Radiculopathy. Spine, 1991, 16, 623-628.	2.0	34
60	Effects of Misattribution in Assigning Cause of Death on Prostate Cancer Mortality Rates. Annals of Epidemiology, 2003, 13, 450-454.	1.9	34
61	Influence of Age on Incident Diabetes and Cardiovascular Disease in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy. Journal of Urology, 2015, 193, 1226-1231.	0.4	34
62	Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study. Urology, 2015, 85, 92-100.	1.0	34
63	Attitudes and Practices of Primary Care Physicians for Prostate Cancer Screening. American Journal of Preventive Medicine, 1996, 12, 277-281.	3.0	33
64	Sources of glucose variability in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Clinical Endocrinology, 2004, 60, 451-456.	2.4	32
65	Viewpoint: Limiting Prostate Cancer Screening. Annals of Internal Medicine, 2006, 144, 438.	3.9	32
66	The Influence of Patient Race and Social Vulnerability on Urologist Treatment Recommendations in Localized Prostate Carcinoma. Medical Care, 2006, 44, 1137-1141.	2.4	32
67	Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1240-1250.	2.5	32
68	Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995–2012. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 259-263.	2.5	32
69	Racial and ethnic disparities in the control of cardiovascular disease risk factors in Southwest American veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study. BMC Health Services Research, 2006, 6, 58.	2.2	31
70	Effect of Preventing <i>Staphylococcus Aureus</i> Carriage on Rates of Peritoneal Catheter-Related Staphylococcal Infections. Literature Synthesis. Peritoneal Dialysis International, 2001, 21, 471-479.	2.3	30
71	Prostate cancer incidence among American Indian and Alaska Native men, US, 1999-2004. Cancer, 2008, 113, 1203-1212.	4.1	28
72	Five-Year Downstream Outcomes Following Prostate-Specific Antigen Screening in Older Men. JAMA Internal Medicine, 2013, 173, 866.	5.1	28

#	Article	IF	Citations
73	Medical Center Characteristics Associated with PSA Screening in Elderly Veterans with Limited Life Expectancy. Journal of General Internal Medicine, 2012, 27, 653-660.	2.6	27
74	Colorectal Cancer Screening in Vulnerable Patients. American Journal of Preventive Medicine, 2016, 51, 454-462.	3.0	26
75	Factors affecting hypoglycemia awareness in insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice, 2004, 65, 61-67.	2.8	24
76	Evaluating Once- and Twice-Daily Self-Monitored Blood Glucose Testing Strategies for Stable Insulin-Treated Patients With Type 2 Diabetes : The Diabetes Outcomes in Veterans Study. Diabetes Care, 2002, 25, 1744-1748.	8.6	23
77	Contributions of Weekly Mean Blood Glucose Values to Hemoglobin A1c in Insulin-Treated Type 2 Diabetes: The Diabetes Outcomes in Veterans Study (DOVES). American Journal of the Medical Sciences, 2004, 327, 319-323.	1.1	23
78	Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. Journal of General Internal Medicine, 2015, 30, 924-934.	2.6	23
79	Barriers to colorectal cancer screening: physician and general population perspectives, New Mexico, 2006. Preventing Chronic Disease, 2011, 8, A35.	3.4	23
80	Classification of the degree of obesity by body mass index or by deviation from ideal weight. Journal of Parenteral and Enteral Nutrition, 2003, 27, 340-348.	2.6	22
81	Diabetes mellitus and healthâ€related quality of life in prostate cancer: 5â€year results from the Prostate Cancer Outcomes Study. BJU International, 2011, 107, 1223-1231.	2.5	22
82	Self-reported volume of radical prostatectomies among urologists in the USA. BJU International, 2007, 99, 339-343.	2.5	21
83	Variation in recommendations for cancer screening among primary care physicians in New Mexico. Journal of Community Health, 1999, 24, 253-267.	3.8	20
84	Association Between Angina and Treatment Satisfaction after Myocardial Infarction. Journal of General Internal Medicine, 2008, 23, 1-6.	2.6	19
85	Colorectal Cancer Screening in the Elderly: The Need for Informed Decision Making. Journal of General Internal Medicine, 2009, 24, 1336-1337.	2.6	19
86	Relationship between home glucose testing and hemoglobin Alc in type II diabetes patients. American Journal of Health-System Pharmacy, 1997, 54, 1062-1065.	1.0	18
87	What Happens After an Elevated PSA Test: The Experience of 13,591 Veterans. Journal of General Internal Medicine, 2010, 25, 1205-1210.	2.6	17
88	Hypoglycemia in stable, insulin-treated veterans with type 2 diabetes. Journal of Diabetes and Its Complications, 2005, 19, 10-17.	2.3	16
89	Prostate Cancer Deaths and Incident Cases Among American Indian/Alaska Native Men, 1999–2009. American Journal of Public Health, 2014, 104, S439-S445.	2.7	16
90	Treatment patterns for older veterans with localized prostate cancer. Cancer Epidemiology, 2015, 39, 769-777.	1.9	16

#	Article	IF	Citations
91	The Centers for Medicare & Medicaid Services Requirement for Shared Decision-making for Lung Cancer Screening. JAMA - Journal of the American Medical Association, 2021, 325, 933.	7.4	16
92	Prostate-specific antigen testing practices and outcomes. Journal of General Internal Medicine, 1998, 13, 106-110.	2.6	15
93	Food frequency questionnaire results correlate with metabolic control in insulin-treated veterans with type 2 diabetes: The diabetes outcomes in veterans study. Journal of the American Dietetic Association, 2004, 104, 1816-1826.	1.1	15
94	Latent variable modelling of recovery trajectories: sexual function following radical prostatectomy. Statistics in Medicine, 2004, 23, 2875-2893.	1.6	15
95	Improving the Communication of Benefits and Harms of Treatment Strategies: Decision Aids for Localized Prostate Cancer Treatment Decisions. Journal of the National Cancer Institute Monographs, 2012, 2012, 197-201.	2.1	15
96	Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Prostate Cancer and Prostatic Diseases, 2014, 17, 338-342.	3.9	15
97	The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. European Urology, 2015, 67, 1019-1025.	1.9	15
98	The Prevalence of Tobacco Use at Federally Qualified Health Centers in the United States, 2013. Preventing Chronic Disease, 2017, 14, E29.	3.4	15
99	Reliability and Validity of the DCP Among Hispanic Veterans. Evaluation and the Health Professions, 2005, 28, 447-463.	1.9	14
100	Moving Towards Shared Decision Making in Prostate Cancer Screening. Journal of General Internal Medicine, 2007, 22, 1056-1057.	2.6	14
101	Decisionâ€making processes among men with lowâ€risk prostate cancer: A survey study. Psycho-Oncology, 2018, 27, 325-332.	2.3	14
102	Rural–Urban Differences in Colorectal Cancer Screening Capacity in Arizona. Journal of Community Health, 2009, 34, 523-528.	3.8	13
103	Surveillance of Colorectal Cancer Screening in New Mexico Hispanics and Non-Hispanic Whites. Journal of Community Health, 2012, 37, 1279-1288.	3.8	13
104	Colorectal Cancer Incidence and Mortality Disparities in New Mexico. Journal of Cancer Epidemiology, 2014, 2014, 1-8.	1.1	13
105	Risk factor management in stable, insulin-treated patients with Type 2 diabetes. Journal of Diabetes and Its Complications, 2003, 17, 186-191.	2.3	12
106	Hypoglycemia in stable, insulin-treated veterans with type 2 diabetes Aprospective study of 1662 episodes. Journal of Diabetes and Its Complications, 2005, 19, 10-17.	2.3	12
107	Blood Glucose Monitoring is Associated with Better Glycemic Control in Type 2 Diabetes: A Database Study. Journal of General Internal Medicine, 2009, 24, 48-52.	2.6	12
108	Knowledge and values for cancer screening decisions: Results from a national survey. Patient Education and Counseling, 2016, 99, 624-630.	2.2	12

#	Article	IF	CITATIONS
109	Randomized trial results did not resolve controversies surrounding prostate cancer screening. Current Opinion in Urology, 2010, 20, 189-193.	1.8	11
110	Statin Medications Are Associated With a Lower Probability of Having an Abnormal Screening Prostate-specific Antigen Result. Urology, 2014, 84, 1058-1065.	1.0	11
111	Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review. PLoS ONE, 2016, 11, e0153417.	2.5	11
112	Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management. Journal of Urology, 2016, 196, 734-740.	0.4	11
113	Racial–Ethnic Disparities in Late-Stage Colorectal Cancer Among Hispanics and Non-Hispanic Whites of New Mexico. Hispanic Health Care International, 2017, 15, 180-188.	0.9	11
114	Why men with a low-risk prostate cancer select and stay on active surveillance: A qualitative study. PLoS ONE, 2019, 14, e0225134.	2.5	11
115	Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study. Prostate Cancer and Prostatic Diseases, 2022, 25, 100-108.	3.9	11
116	Reconciling Primary Care and Specialist Perspectives on Prostate Cancer Screening. Annals of Family Medicine, 2012, 10, 568-571.	1.9	10
117	Comparing the effect of a decision aid plus patient navigation with usual care on colorectal cancer screening completion in vulnerable populations: study protocol for a randomized controlled trial. Trials, 2014, 15, 275.	1.6	10
118	Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. Medical Decision Making, 2019, 39, 962-974.	2.4	10
119	An Argument Against Routine Prostate Cancer Screening. Archives of Internal Medicine, 2003, 163, 663.	3.8	9
120	The Cautionary Tale of PSA Testing. Archives of Internal Medicine, 2010, 170, 1262-3.	3.8	9
121	The Superiority of Patient Engagement and Shared Decision-Making in Noninferiority Trials. Journal of General Internal Medicine, 2014, 29, 16-17.	2.6	9
122	Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study. Translational Behavioral Medicine, 2018, 8, 156-165.	2.4	9
123	A population-based survey of prostate cancer testing in New Mexico. Journal of Community Health, 1999, 24, 409-419.	3.8	8
124	Comparative effectiveness research in localized prostate cancer treatment. Journal of Comparative Effectiveness Research, 2013, 2, 583-593.	1.4	8
125	Physicians' Perceptions of Factors Influencing the Treatment Decision-making Process for Men With Low-risk Prostate Cancer. Urology, 2017, 107, 86-95.	1.0	8
126	Prostate Cancer Testing following a Negative Prostate Biopsy: Over Testing the Elderly. Journal of General Internal Medicine, 2007, 22, 1139-1143.	2.6	7

#	Article	IF	Citations
127	Statin use does not prevent recurrent adenomatous polyp formation in a VA population. Indian Journal of Gastroenterology, 2010, 29, 106-111.	1.4	7
128	Weight deficit in patients on continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 2002, 39, 1068-1077.	1.9	6
129	The complicated †Yes': Decision-making processes and receptivity to lung cancer screening among head and neck cancer survivors. Patient Education and Counseling, 2018, 101, 1741-1747.	2.2	6
130	Post-imaging pulmonary nodule mathematical prediction models: are they clinically relevant?. European Radiology, 2019, 29, 5367-5377.	4.5	6
131	Rising Use of Multitarget Stool DNA Testing for Colorectal Cancer. JAMA Network Open, 2021, 4, e2122328.	5.9	6
132	New Mexico's capacity for increasing the prevalence of colorectal cancer screening with screening colonoscopies. Preventing Chronic Disease, 2005, 2, A07.	3.4	6
133	α-Tocopherol Supplementation for Men with Existing Coronary Artery Disease: A Feasibility Study. Preventive Medicine, 1999, 29, 112-118.	3.4	5
134	Probability of an Abnormal Screening Prostate-specific Antigen Result Based on Age, Race, and Prostate-specific Antigen Threshold. Urology, 2014, 83, 599-605.	1.0	5
135	Physicians' perspectives on the informational needs of low-risk prostate cancer patients. Health Education Research, 2017, 32, 134-152.	1.9	5
136	Attitudes of Clinicians about Screening Head and Neck Cancer Survivors for Lung Cancer Using Low-Dose Computed Tomography. Annals of Otology, Rhinology and Laryngology, 2020, 129, 23-31.	1.1	5
137	Lung Cancer Staging at Diagnosis in the Veterans Health Administration: Is Rurality an Influencing Factor? A Crossâ€Sectional Study. Journal of Rural Health, 2020, 36, 484-495.	2.9	5
138	What we have learned from randomized trials of prostate cancer screening. Asian Journal of Andrology, 2011, 13, 369-373.	1.6	5
139	A public-health perspective on screening colonoscopy. Expert Review of Anticancer Therapy, 2011, 11, 561-569.	2.4	4
140	Along the way to developing a theory of the program: A re-examination of the conceptual framework as an organizing strategy. Evaluation and Program Planning, 2014, 45, 157-163.	1.6	4
141	Implications of the New USPSTF Prostate Cancer Screening Recommendation—Attaining Equipoise. JAMA Internal Medicine, 2018, 178, 889.	5.1	4
142	Comparative effectiveness of five fecal immunochemical tests using colonoscopy as the gold standard: study protocol. Contemporary Clinical Trials, 2021, 106, 106430.	1.8	4
143	Psychological predictors of delayed active treatment following active surveillance for lowâ€risk prostate cancer: The Patient REported outcomes for Prostate cARE prospective cohort study. BJUI Compass, 2022, 3, 226-237.	1.3	4
144	Using multiple cutpoints for the free-to-total prostate specific antigen ratio improves the accuracy of prostate cancer detection. Prostate, 2002, 52, 150-158.	2.3	3

#	Article	IF	CITATIONS
145	Misclassifying the indications for prostate-specific antigen testing may bias case–control studies of the efficacy of prostate cancer screening. Journal of Clinical Epidemiology, 2004, 57, 1071-1075.	5.0	3
146	Battling Prostate Cancer with 5-Alpha-Reductase Inhibitors: a Pyrrhic Victory?. Journal of General Internal Medicine, 2011, 26, 798-801.	2.6	3
147	Disparities in Stage at Presentation and Treatment of Colorectal Cancer among Hispanic and Non-Hispanic White Patients. American Surgeon, 2015, 81, 353-355.	0.8	3
148	Disparities in Stage at Presentation and Treatment of Colorectal Cancer among Hispanic and Non-Hispanic White Patients. American Surgeon, 2015, 81, E353-5.	0.8	3
149	Striking the Right Balance With Prostate Cancer Screening. JAMA Network Open, 2022, 5, e222174.	5.9	3
150	The Future of EEG Technology. The American Journal of EEG Technology, 1972, 12, 53-64.	0.3	2
151	Nutrition Indices in Obese Continuous Peritoneal Dialysis Patients with Inadequate and Adequate Urea Clearance. Peritoneal Dialysis International, 2002, 22, 506-512.	2.3	2
152	In persons at average risk, stool DNA tests had higher sensitivity than FIT for detecting colorectal cancer. Annals of Internal Medicine, 2014, 161, JC10.	3.9	2
153	Review: little high-quality evidence is available regarding treatments for localised prostate cancer. Evidence-Based Medicine, 2008, 13, 139-139.	0.6	1
154	Making the grade: The newest US Preventive Services Task Force prostate cancer screening recommendation. Cancer, 2017, 123, 3875-3878.	4.1	1
155	PSA Thresholds for Prostate Cancer Detection. JAMA - Journal of the American Medical Association, 1997, 278, 700.	7.4	0
156	Clinical updates: A new feature in JGIM. Journal of General Internal Medicine, 2006, 21, 1343-1343.	2.6	0
157	Teaching Tips—A new series in JGIM. Journal of General Internal Medicine, 2008, 23, 112-113.	2.6	0
158	Response. Journal of the National Cancer Institute, 2014, 106, djt466-djt466.	6.3	0
159	Editorial Comment. Journal of Urology, 2014, 192, 728-728.	0.4	0